- The New Expanded Partnership Will Aim to Support the
Dismantling of Systemic Barriers to Equity and Help Strengthen the
Health Workforce in Massachusetts
- The Existing Global Partnership Has Provided Screening and
Diagnostic Services to Over 8 Million People in Community
Settings
Takeda (TSE:4502/NYSE:TAK) announced that it has expanded its
partnership with Partners In Health (PIH), an international
nonprofit organization, to support a new initiative with PIH that
aims to address social determinants of health and improve access to
care within communities across Massachusetts. This builds on
Takeda’s existing global partnership with PIH that has been in
place since 2017.
Takeda’s work with PIH has focused on strengthening the capacity
of communities globally to identify and address health inequities
sustainably, leading to improved care at every stage of the patient
journey. Takeda has supported PIH in expanding and strengthening
its diagnostic and clinical care services to over 8 million people
in community settings since the global partnership was
initiated.
In this new partnership, Takeda and PIH will focus on achieving
the following objectives:
- Establishing additional Health Equity Communities of Practice
that will convene leaders to target systemic barriers to equity at
the policy level
- Expanding the capacity of local health departments and
communities to plan for and deliver programs with a focus on health
equity and community inclusion
- Expanding opportunities for community health workers to
strengthen the health workforce and bring more community members
into the health system
“Our collaboration with Takeda will help advance more equitable
community health systems in Massachusetts,” said Kristina St. Cyr
Kimani, Massachusetts director of Partners In Health United States.
“By centering community-driven approaches and supporting local
health departments, we aim to dismantle systemic barriers to health
and wellbeing and reimagine health and social support services to
better meet the needs of diverse communities in Massachusetts.”
In Massachusetts, there are significant gaps in health outcomes
based on one’s race, ethnicity, socioeconomic status and other
factors. A report by the Blue Cross Blue Shield of Massachusetts
Foundation and the Health Equity Compact revealed that communities
of color in Massachusetts face an economic burden of 1.5 billion in
avoidable health care spending due to poorer health.1 The study
estimates that the growing burden will exceed $11 billion annually
by 2050.1
“Expanding our collaboration with PIH will help improve health
outcomes in communities disproportionately affected by health care
disparities,” said Dr. Chris Reddick, vice president and head of
U.S. Health Equity, CSR and Philanthropy at Takeda. “This
partnership takes a holistic look at a multitude of factors that
affect one’s health and leverages community health improvement
plans to ensure community members are connected to the health care
resources they need most. Through this approach, additional
communities across Massachusetts will be served, including those
that surround our global hub in Cambridge.”
To alleviate the growing burden of health care disparities,
Takeda is committed to collaborating with community partners to
support sustainable health equity solutions that target the root
cause of health inequities with the ultimate goal of improving
health and creating a brighter future for all.
Learn more about how Takeda is working alongside community
partners in the Caring for Tomorrow: 2023 U.S. Community Impact
Report: Takeda_CSR_Report_2023.pdf
About Takeda Takeda is focused on creating better
health for people and a brighter future for the world. We aim to
discover and deliver life-transforming treatments in our core
therapeutic and business areas, including gastrointestinal and
inflammation, rare diseases, plasma-derived therapies, oncology,
neuroscience and vaccines. Together with our partners, we aim to
improve the patient experience and advance a new frontier of
treatment options through our dynamic and diverse pipeline. As a
leading values-based, R&D-driven biopharmaceutical company
headquartered in Japan, we are guided by our commitment to
patients, our people and the planet. Our employees in approximately
80 countries and regions are driven by our purpose and are grounded
in the values that have defined us for more than two centuries. For
more information, visit www.takeda.com.
Important Notice For the purposes of this notice,
“press release” means this document, any oral presentation, any
question and answer session and any written or oral material
discussed or distributed by Takeda Pharmaceutical Company Limited
(“Takeda”) regarding this release. This press release (including
any oral briefing and any question-and-answer in connection with
it) is not intended to, and does not constitute, represent or form
part of any offer, invitation or solicitation of any offer to
purchase, otherwise acquire, subscribe for, exchange, sell or
otherwise dispose of, any securities or the solicitation of any
vote or approval in any jurisdiction. No shares or other securities
are being offered to the public by means of this press release. No
offering of securities shall be made in the United States except
pursuant to registration under the U.S. Securities Act of 1933, as
amended, or an exemption therefrom. This press release is being
given (together with any further information which may be provided
to the recipient) on the condition that it is for use by the
recipient for information purposes only (and not for the evaluation
of any investment, acquisition, disposal or any other transaction).
Any failure to comply with these restrictions may constitute a
violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns
investments are separate entities. In this press release, “Takeda”
is sometimes used for convenience where references are made to
Takeda and its subsidiaries in general. Likewise, the words “we”,
“us” and “our” are also used to refer to subsidiaries in general or
to those who work for them. These expressions are also used where
no useful purpose is served by identifying the particular company
or companies.
Forward-Looking Statements This press release and
any materials distributed in connection with this press release may
contain forward-looking statements, beliefs or opinions regarding
Takeda’s future business, future position and results of
operations, including estimates, forecasts, targets and plans for
Takeda. Without limitation, forward-looking statements often
include words such as “targets”, “plans”, “believes”, “hopes”,
“continues”, “expects”, “aims”, “intends”, “ensures”, “will”,
“may”, “should”, “would”, “could”, “anticipates”, “estimates”,
“projects” or similar expressions or the negative thereof. These
forward-looking statements are based on assumptions about many
important factors, including the following, which could cause
actual results to differ materially from those expressed or implied
by the forward-looking statements: the economic circumstances
surrounding Takeda’s global business, including general economic
conditions in Japan and the United States; competitive pressures
and developments; changes to applicable laws and regulations,
including global health care reforms; challenges inherent in new
product development, including uncertainty of clinical success and
decisions of regulatory authorities and the timing thereof;
uncertainty of commercial success for new and existing products;
manufacturing difficulties or delays; fluctuations in interest and
currency exchange rates; claims or concerns regarding the safety or
efficacy of marketed products or product candidates; the impact of
health crises, like the novel coronavirus pandemic, on Takeda and
its customers and suppliers, including foreign governments in
countries in which Takeda operates, or on other facets of its
business; the timing and impact of post-merger integration efforts
with acquired companies; the ability to divest assets that are not
core to Takeda’s operations and the timing of any such
divestment(s); and other factors identified in Takeda’s most recent
Annual Report on Form 20-F and Takeda’s other reports filed with
the U.S. Securities and Exchange Commission, available on Takeda’s
website at:
https://www.takeda.com/investors/sec-filings-and-security-reports/
or at www.sec.gov. Takeda does not undertake to update any of the
forward-looking statements contained in this press release or any
other forward-looking statements it may make, except as required by
law or stock exchange rule. Past performance is not an indicator of
future results and the results or statements of Takeda in this
press release may not be indicative of, and are not an estimate,
forecast, guarantee or projection of Takeda’s future results.
References:
1J. Gaskin, D., A. LaVeist, T., Turner, A., & Obbin, S.
(2023). The Time is Now: The $5.9 Billion Case for Massachusetts
Health Equity Reform. The Blue Cross Blue Shield of Massachusetts
Foundation.
https://www.bluecrossmafoundation.org/sites/g/files/csphws2101/files/2023-06/Econ_Cost_Inequities_Full%20report_FINAL_0.pdf
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240611689645/en/
U.S. and International Media Megan Ostrower
megan.ostrower@takeda.com +1 772-559-4924
Takeda Pharmaceutical (NYSE:TAK)
Historical Stock Chart
From Nov 2024 to Dec 2024
Takeda Pharmaceutical (NYSE:TAK)
Historical Stock Chart
From Dec 2023 to Dec 2024
